<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PCR-based preemptive therapy with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> has been shown to reduce the incidence of CMV disease after BMT </plain></SENT>
<SENT sid="1" pm="."><plain>Failures of this treatment strategy are CMV disease and secondary non-<z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Eighty-six consecutive patients at high risk for CMV disease who received PCR-based preemptive therapy with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> were assessed for treatment failures and possible risk factors </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="465284">Ganciclovir</z:chebi> was initiated in 57 of 86 patients (66%) </plain></SENT>
<SENT sid="4" pm="."><plain>Only 28 of 86 (32%) patients received 4 or more weeks of <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Recurrence of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> after successful treatment was more frequent among recipients of a BMT from an unrelated compared to a sibling donor (P = 0.004) </plain></SENT>
<SENT sid="6" pm="."><plain>Three (3.5%) patients developed non-fatal early <z:hpo ids='HP_0003674'>onset</z:hpo> CMV disease and seven of 68 (10.3 %) <z:hpo ids='HP_0003584'>late onset</z:hpo> CMV disease (&gt;100 days post transplant) </plain></SENT>
<SENT sid="7" pm="."><plain>Risk factors for <z:hpo ids='HP_0003584'>late onset</z:hpo> CMV disease were cGVHD (P = 0.0017) and duration of prior antiviral therapy &gt;4 weeks (P = 0 </plain></SENT>
<SENT sid="8" pm="."><plain>0073) </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence of secondary non-<z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was 28% with the duration of antiviral treatment being a significant risk factor for secondary <z:mp ids='MP_0001794'>bacterial</z:mp> (P = 0.0045) and invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> (P = 0.006) </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, PCR-based preemptive treatment with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> reduces early <z:hpo ids='HP_0003674'>onset</z:hpo> CMV disease, but the duration of antiviral therapy prior to day +100 is a significant risk factor for <z:hpo ids='HP_0003584'>late onset</z:hpo> CMV disease as well as secondary non-<z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
</text></document>